Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer’s growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.
Researchers in Professor David Tuveson’s laboratory at Cold Spring Harbor Laboratory (CSHL) think it’s possible to do better with a different type of treatment. Part of the problem, they say, is that cancer cells in the pancreas are protected by the dense matrix that surrounds them. The matrix is a mixture of extracellular components and noncancerous cells known as the stroma. All solid tumors contain stroma. In pancreatic cancers, this fibrous material is particularly abundant, making up nearly 90 percent of a tumor’s mass. This stroma impedes anticancer drugs’ from getting to their targets. Additionally, stromal cells secrete factors that actually help the tumors grow.
Overcoming the stroma’s protective influence has been challenging, but new leads from Tuveson’s team, as reported on October 26, 2018 in the journal Cancer Discovery, point to a promising strategy. In fact, the new findings suggest that drugs which target the right cellular pathways can do more than just thwart tumor-supporting cells in the stroma. They may recruit them into the anticancer fight.
A key element of the stroma is a type of cell called a fibroblast. Fibroblasts manufacture the stroma’s connective tissue. They also generate factors that promote cancer cell growth and prevent the immune system from attacking the cancerous cells. Last year Tuveson’s team discovered that the stroma of pancreatic tumors contains at least two types of fibroblasts. One type show features known to support tumor growth, the other type appear to have the opposite effect.
The good news is that the fibroblasts’ identities are not fixed. With the right cues, tumor-promoting fibroblasts can become tumor-restrictors.
“These cells can convert into one another, depending on the cues they get from the microenvironment and from the cancer cells,” explains Giulia Biffi, a postdoctoral researcher in Tuveson’s lab who led the new study. “This is potentially useful because, in theory, you can shift the tumor-promoting cells to tumor-restraining, rather than just depleting the tumor-promoting cells.”
In this new report, Biffi and her colleagues have identified specific molecular signals released by cancer cells that determine fibroblasts’ character within pancreatic tumors. They have discovered that one such molecule, IL-1, drives fibroblasts to take on a tumor-promoting identity. They have also shown how another molecule, TGF-beta, overrides that signal and keeps fibroblasts in a potentially anticancer state even when IL-1 is present.
The researchers are now exploring what happens to pancreatic tumors when they manipulate IL-1 and TGF-beta signaling and convert tumor-promoting fibroblasts to a more beneficial state. They will also investigate what happens when they target these pathways in combination with chemotherapy or cancer immunotherapies. Ultimately, Biffi says, patients may benefit most from a combination of therapies that target both the cancer cells and parts of the microenvironment that support their growth.
Learn more: Turning cells against pancreatic cancer
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Alex Trebek, who is battling pancreatic cancer, sends ‘Jeopardy!’ fans a hopeful message on April 17, 2019 at 10:01 pm
Alex Trebek signed off following the final day of taping for the 35th year of “Jeopardy!”, and he told fans of the popular game show that he planned to return later this year for another season of ... […]
- Achilles’ heel of pancreatic cancer may lead to improved patient treatment on April 17, 2019 at 9:14 pm
Scientists may have discovered the “Achilles’ heel” of pancreatic cancer – a condition which is notoriously difficult to treat. Researchers believe a protein called leukaemia inhibitory factor (LIF) ... […]
- Alex Trebek says he's 'feeling good' amid cancer battle, plans to host 'Jeopardy!' season 36 on April 17, 2019 at 6:54 pm
FOX NEWS - Cancer won't slow down "Jeopardy!" host Alex Trebek. He's filmed 50 episodes since being diagnosed with pancreatic cancer in March and in a new video update to fans on Wednesday, said he's ... […]
- WATCH: ‘Jeopardy’ host Alex Trebek gives update on his progress after pancreatic cancer diagnosis. ‘I’m touched beyond words.’ on April 17, 2019 at 6:37 pm
When Alex Trebek announced in March that he had been diagnosed with stage 4 pancreatic cancer, “Jeopardy!" fans rallied to support him. Trebek vowed to stay on the job, even as he sought treatment — ... […]
- Dr. Tempero on Role of Molecular Profiling in Pancreatic Cancer on April 17, 2019 at 3:02 pm
Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor ... […]
- Some Dying Cancer Patients Still Receive Active Therapies on April 17, 2019 at 1:30 pm
Older patients with lung cancer were less likely to receive radiotherapy. The odds of receiving chemotherapy and radiotherapy were also lower for lung and pancreatic cancer patients who had higher ... […]
- New study targets Achilles' heel of pancreatic cancer, with promising results on April 17, 2019 at 1:00 pm
Advanced pancreatic cancer is often symptomless, leading to late diagnosis only after metastases have spread throughout the body. Now, researchers have uncovered the role of a signaling protein, ... […]
- 'Mami's Message' to raise money for pancreatic cancer research on April 17, 2019 at 11:34 am
Natalia Piferrer and her mother used to spend every birthday going out to dinner and making wishes on candles. This year, Piferrer will spend her mother’s birthday making with another wish: to raise ... […]
- Key protein a possible new target in the treatment of pancreatic cancer on April 17, 2019 at 10:21 am
WOODBURY, N.Y., April 17, 2019 -- Pancreatic cancer can be difficult to treat and often responds poorly to chemotherapy due to the presence of tumor cells located within the dense protective tissue, ... […]
via Bing News